Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 50 | 1.930 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 7 | 1.810 |
Why?
|
| Skin Diseases | 1 | 2023 | 2 | 0.890 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 11 | 0.870 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 50 | 0.830 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 115 | 0.800 |
Why?
|
| Prognosis | 4 | 2023 | 216 | 0.520 |
Why?
|
| Child | 6 | 2023 | 3348 | 0.430 |
Why?
|
| Humans | 8 | 2023 | 6929 | 0.390 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 2 | 0.360 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 2 | 0.360 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 3 | 0.360 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 3 | 0.360 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 4 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 67 | 0.340 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2023 | 3 | 0.240 |
Why?
|
| Mexico | 1 | 2023 | 5 | 0.240 |
Why?
|
| Acute Disease | 1 | 2023 | 77 | 0.230 |
Why?
|
| Incidence | 1 | 2023 | 134 | 0.230 |
Why?
|
| Thioguanine | 1 | 2023 | 8 | 0.220 |
Why?
|
| Stem Cell Transplantation | 1 | 2023 | 15 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2023 | 24 | 0.220 |
Why?
|
| Blood Component Removal | 1 | 2022 | 1 | 0.210 |
Why?
|
| Leukemia | 1 | 2022 | 15 | 0.210 |
Why?
|
| Retrospective Studies | 2 | 2023 | 1337 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2021 | 3 | 0.200 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2021 | 4 | 0.200 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 5 | 0.200 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 5 | 0.190 |
Why?
|
| Shock, Septic | 1 | 2021 | 5 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 7 | 0.190 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 31 | 0.180 |
Why?
|
| Neuroblastoma | 1 | 2019 | 14 | 0.180 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 56 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2021 | 649 | 0.120 |
Why?
|
| Adolescent | 3 | 2021 | 2183 | 0.110 |
Why?
|
| Female | 3 | 2021 | 3534 | 0.100 |
Why?
|
| Filgrastim | 1 | 2010 | 2 | 0.090 |
Why?
|
| Benzylamines | 1 | 2010 | 2 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 52 | 0.090 |
Why?
|
| Recurrence | 1 | 2010 | 121 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 641 | 0.080 |
Why?
|
| Adult | 2 | 2022 | 1199 | 0.080 |
Why?
|
| Multiple Organ Failure | 1 | 2022 | 1 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2022 | 4 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2022 | 2 | 0.050 |
Why?
|
| Critical Illness | 1 | 2022 | 22 | 0.050 |
Why?
|
| MyoD Protein | 1 | 2021 | 4 | 0.050 |
Why?
|
| BK Virus | 1 | 2021 | 3 | 0.050 |
Why?
|
| Infusion Pumps | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mucormycosis | 1 | 2021 | 4 | 0.050 |
Why?
|
| Disease Management | 1 | 2021 | 36 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 98 | 0.050 |
Why?
|
| Mutation | 1 | 2021 | 213 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 33 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 19 | 0.040 |
Why?
|
| Infant | 1 | 2021 | 1449 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 1562 | 0.030 |
Why?
|
| Male | 1 | 2019 | 3367 | 0.020 |
Why?
|